Promising cell therapy offers hope for relapsed or refractory T-Cell Leukaemia
Oct 05, 2024
Singapore, October 5: A new cell therapy, targeting CD7 on leukaemia cells, gives a potentially effective treatment for patients with T-cell acute lymphoblastic leukaemia (T-ALL) who have exhausted all standard treatment options. Published in the prestigious medical journal Nature Medicine on 3 September 2024[1], the study highlights the effectiveness of a new chimeric antigen receptor (CAR) T-cell therapy.
Read More...
